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Cancer omics data are exponentially created and associated with clinical variables, and important
ﬁndings can be extracted based on bioinformatics approaches which can then be experimentally
validated. Many of these ﬁndings are related to a speciﬁc class of non-coding RNA molecules called
microRNAs (miRNAs) (post-transcriptional regulators of mRNA expression). The related research
ﬁeld is quite heterogeneous and bioinformaticians, clinicians, statisticians and biologists, as well
as data miners and engineers collaborate to cure stored data and on new impulses coming from
the output of the latest Next Generation Sequencing technologies.
Here we review the main research ﬁndings on miRNA of the ﬁrst 10 years in colon cancer research
with an emphasis on possible uses in clinical practice. This review intends to provide a road map in
the jungle of publications of miRNA in colorectal cancer, focusing on data availability and new ways
to generate biologically relevant information out of these huge amounts of data.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction are still far from truly understanding the extent of the involvementResearch in the past decade has shown that several types of
non-coding RNAs (ncRNAs, an RNA molecule that is not translated
into a protein but has other important biological functions), includ-
ing long ncRNAs and notably microRNAs (miRNAs), are involved in
cancer development and progression [1]. NcRNAs are classiﬁed
based on their size and known function. In this review we focus
on miRNAs, since they are the most widely studied class of ncRNAs,
although many issues about mining the data remain unsolved. Weal Societies. Published by Elsevier
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Core Facility, SIB j Swiss
énopode, CH-1015 Lausanne,of miRNAs in cancer, many results have been produced with the ﬁ-
nal aim of ﬁnding biomarkers for personalized (intended as the P5
concept in its entirety) [2] therapy, but still much must be done in
integrating different omics data, validation of results in large co-
horts of patients, evaluation of the treatments’ risks, as well as so-
cio-economic plans of what can be really done with the available
resources [3]. Colorectal cancer (CRC) is one of the most common
malignancies in the western world. Up to 90% of patients can be
cured by surgery if the disease is detected at the early stage, but
unfortunately it is often diagnosed only at an advanced stage and
the prognosis is therefore poor. Synchronous metastases are pres-
ent in 15–25% of CRC patients and since patients with synchronous
colorectal liver metastases comprise at least 25% of patients re-
ported from large resection series, determination of the optimal
management of these patients, in terms of classifying subgroup
of patients to avoid over- or under-treatment, possibly avoiding
the progression of the disease, is of fundamental importance [4],
and miRNAs have the potentiality to be the main actor in this sche-
ma, being them regulators of mRNAs, situated in fragile sites [5],
involved in cancer biology and having decoy activity [6].B.V. Open access under CC BY-NC-ND license.
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miRNAs are short (19-23-nucleotides) RNAs that are processed
from hairpin loop structures and control the translation of mRNA
into protein. The role of miRNAs in cell physiology and pathology
is hard to understand due to their complex relation to biological
function:
1. a typical miRNA can control translation of more than one mes-
senger RNA, [7] perhaps as many as a few thousand messenger
RNAs [8] and,
2. a single messenger can be controlled post-transcriptionally by
more than 1 miRNA [9], perhaps dozens [8,10].
The literature related to miRNAs, has grown exponentially in
the last decade, in summary we know that [11,12]:
 miRNAs can act as oncogenes or tumor-suppressor genes.
 miRNAs are involved in tumor progression and metastasis
through their role in pathways that contribute to metastasis,
including migration, invasion, cell proliferation, epithelial-to-
mesenchymal transition (EMT), angiogenesis, and apoptosis.
 miRNAs might be useful as prognostic and predictive markers.
But how are these intermediate results linked together and with
other omics data? Have they been analyzed associated to already
known subgroups of patients like KRAS mutated, BRAF mutated
[13], BRAF-like [14]? Are they particular for CRC or might they
be general for cancer? How many studies failed or had discordant
results on the same miRNAs when analyzed in different cohorts?
1.2. Public data
The development of miRNA microarrays, RT-PCR platforms and
deep sequencing methodologies resulted in the acquisition of a
growing number of miRNA proﬁling studies, and has paved the
way to new approaches for biomarker discovery. Some of the pub-
lished miRNA proﬁles are publicly available in the NCBI Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/), ArrayEx-
press (http://www.ebi.ac.uk/arrayexpress/), miRNA body map
(http://www.mirnabodymap.org), TCGA (http://cancergenome.nih.
gov) and SMIRNADB (http://www.mirz.unibas.ch).
Two tools offer compact visualizations of uploaded miRNA
expression differences:
1. The Geo proﬁles tool (http://www.ncbi.nlm.nih.gov/geopro-
ﬁles) among uploaded samples.
2. The Gene Expression Atlas (http://www.ebi.ac.uk/gxa/) per
organism and per experimental condition.
The TCGA project (https://tcga-data.nci.nih.gov/tcga/tcga-
Home2.jsp) provides multiple omics data for the same set of sam-
ples. Mirnabodymap (http://www.mirnabodymap.org/) contains
RT-qPCR data on cancer (but not yet for CRC).
For CRC, more than 1400 arrays are available in GEO, 873 arrays
in ArrayExpress and 187 microRNASeq samples are downloadable
from the TCGA database. SMIRNADB contains miRNA and other
ncRNA expression data in large and small intestinal samples in
the mouse.
1.3. MiRNA proﬁling
The main methods currently used for miRNA proﬁling are
sequencing, microarray, real-time PCR-based approaches and
in situ hybridization (ISH); all of them require standard procedures
to be correctly processed andmined. Initially these techniqueswereapplied on fresh-frozen tissue specimen, but recently reproducible
proﬁles of comparable quality have been obtained also using forma-
lin-ﬁxedparafﬁn-embedded tissue samples (FFPE),makingarchived
tumor tissue collections accessible for study [15,16].
Reis and colleagues reported in 2011 that with FFPE material
the Nanostring technology might be preferable over RT-PCR [17]
notably on older samples with more highly degraded RNA and
DNA [18].
Deep sequencing or Next Generation Sequencing (NGS) plat-
forms have recently emerged as powerful technologies that pro-
vide unprecedented insight into biological systems. Thanks to the
development of NGS technologies, large portions of the human
genome are being re-sequenced in many individuals, opening
new opportunities to ﬁnd out how changes in the genome are asso-
ciated with disease.
This situation poses a number of new challenges to translational
research scientists, especially in regard to requirements for ad-
vanced data management and data analysis procedures and for
teamwork between clinicians, computer scientists, and molecular
biologists.
Therefore, integrative analysis between different omics plat-
forms has become an essential element in the experimental design
of studies in the era of NGS genomics [19].
The ﬁeld of Bioinformatics is undergoing a rapid evolution to
create new tools for NGS data visualization, manipulation, and
analysis in terms of alignment, assembly, quality control and vari-
ations detection.
However, there is a lack of mature high standard data analysis
methods although several open-source applications and utilities
start providing useful tools for data analysts, for example: Galaxy
(http://www.galaxy.psu.edu/, web-based) provides an NGS analy-
sis toolbox for quality control, mapping, SAM tools and several
post-processing analyses.
ISH is another extensively applied technique due to its ability to
detect and localize speciﬁc miRNAs within tissue samples. Among
many others, it has been performed while studying the miR-200c
function in EMT in metastatic colorectal cancer (mCRC) [20]. After
miR-200c expression was found lower in metastasis when com-
pared to normal mucosa, ISH analysis of primary CRC, liver metas-
tasis samples and adjacent hepatocytes suggested what might be
the role of miR-200c during cancer progression, notably during
the EMT-MET (mesenchymal-to-epithelial transition) switching:
modulation of the miR-200c expression could inﬂuence the cell
invasion and the cell proliferation functions during metastasis
development.2. miRNAs in colon cancer
Since the literature dedicated to miRNAs in colon cancer has
grown considerably in the last decade, in Table 1 we report the up-
dated (associations inserted by us are in bold) list of the causal
associations between miRNAs and colon cancer taken from
http://www.mir2disease.org.
The ﬁrst deﬁnite association of miRNAs with CRC was the real-
ization that in 2003 Human homologues of murine miRNA se-
quences, miR-143 and miR-145, consistently display reduced
steady-state levels of the mature miRNA at the adenomatous and
cancer stages of CRC.
Since then, miRNA alterations have been observed in CRC (for a
complete review of miRNAs in CRC diagnosis, prognosis and pro-
gression and possible mechanisms of action, see [21]), but in most
cases the biological signiﬁcance of the observation is not fully
understood and still there is no clear division between those that
are driver events and those that are passenger events without
any physiological importance.
Table 1
miRNAs causal in CRC. Samples source was reported to specify whether CCCLs or SRTs (frozen or FFPE) were analyzed.
miRNA Reference’s title Samples source References
hsa-let-7a-1 let-7 miRNA functions as a potential growth suppressor in human colon cancer cells SRTs [51]
hsa-miR-124a Genetic unmasking of an epigenetically silenced miRNA in human cancer cells CCCLs [52]
hsa-miR-126 The ncRNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase
signaling and is frequently lost in colon cancers.
CCCLs [53]
hsa-miR-127 Speciﬁc activation of microRNA-127 with down regulation of the proto-oncogene BCL6 by chromatin-
modifying drugs in human cancer cells
SRTs (fresh
frozen), CCCLs
[54]
hsa-miR-135 Regulation of the adenomatous polyposis coli gene by the miR-135 family in CRC SRTs (fresh
frozen), CCCLs
[33]
hsa-miR-140 Mechanism of chemo resistance mediated by miR-140 in human osteosarcoma and colon cancer cells SRTs (fresh
frozen), CCCLs
[55]
hsa-miR-141 microRNA-141 Regulates Smad Interacting Protein 1 (SIP1) and inhibits migration and invasion of CRC cells CCCLs [56]
hsa-miR-143 Role of miR-143 targeting KRAS in colorectal tumorigenesis SRTs [51]
hsa-miR-143 microRNAs 143 and 145 are possible common onco-microRNAs in human cancers SRTs [57]
hsa-miR-143 microRNA-143 targets DNA methyltransferases 3A in CRC SRTs (fresh
frozen), CCCLs
[58]
hsa-miR-143 microRNA-143 reduces viability and increases sensitivity to 5-ﬂuorouracil in HCT116 human CRC cells SRTs [36]
hsa-miR-145 Mechanism of growth inhibition by microRNA 145: the role of the IGF-I receptor signaling pathway CCCLs [59]
hsa-miR-145 microRNAs 143 and 145 are possible common onco-microRNAs in human cancers SRTs [57]
hsa-miR-145 microRNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells CCCLs [60]
hsa-miR-145 Diagnostic and prognostic miRNAs in stage II colon cancer SRTs (fresh
frozen)
[61]
hsa-miR-17-92 Augmentation of tumor angiogenesis by a Myc-activated miRNA cluster SRTs (FFPE) [62]
hsa-miR-18a⁄ The miR-18a⁄ miRNA functions as a potential tumor suppressor by targeting on K-Ras CCCLs [63]
hsa-miR-192, has-
miR-194
p53-Responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest CCCLs [64]
hsa-miR-196a High miR-196a levels promote the oncogenic phenotype of CRC cells CCCLs [65]
hsa-miR-21 microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells CCCLs [66]
hsa-miR-21 microRNA-21 (miR-21) post-transcriptionally down regulates tumor suppressor Pdcd4 and stimulates
invasion, intravasation and metastasis in CRC
SRTs (fresh
frozen), CCCLs
[67]
hsa-mir-200 A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in
cancercells
CCCLs [68]
hsa-miR-215 p53-Responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest CCCLs [64]
hsa-miR-342 Epigenetic silencing of the intronic miRNA hsa-miR-342 and its host gene EVL in CRC SRTs (fresh frozen,
FFPE)
[69]
hsa-miR-34a Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in
human colon cancer cells
CCCLs [70]
hsa-miR-34b, has-
miR-34c
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island
methylation in CRC
SRTs, CCCLs [71]
hsa-miR-451 microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of
gastrointestinal cancer cells
SRTs [72]
3002 S. Rossi et al. / FEBS Letters 586 (2012) 3000–3007Luo and Brenner, performed literature mining and published a
useful summary of manually and automatically curated informa-
tion highlighting, which miRNAs have been studied and under
which conditions [22].
In these studies the most promising miRNAs for a role in the
pathogenesis in colon cancer appear to be miR-20a, miR-21,
miR-31, miR-92, miR-181b, which are up-regulated in colon cancer
and miR-143 and miR-145 which are frequently down-regulated in
CRC without a signiﬁcant association with tumor progression
although associated with tumor size [23] and both with decreased
expression in adenomas and carcinomas. Gao and colleagues re-
ported that Evi1 is a transcriptional suppressor of miR-143: their
data pointed to a pathway in which Evi1 suppresses miR-143 gene
transcription which in turn leads to elevated levels of K-Ras [24];
the study was performed on fresh frozen surgically resected
primary tissue and cell lines.
miR-21 was found up-regulated in breast, oral, and CRC tumor
tissues. Volinia et al. found miR-21,as well as miR-17-5p, miR-191,
miR-29b and miR-155 to be up-regulated at least in CRC. Schetter
et al. found miR-21 to be positively correlated with higher stage
and of prognostic value [25]: expression proﬁling of colon adeno-
carcinoma and paired normal tissues was performed on a US train-
ing cohort by miRNA microarray and validated in a Chinese cohort
by RT-PCR. Associations with tumor status, TNM staging, survival
prognosis, and response to adjuvant chemotherapy were evalu-
ated. High miR-21 expression was associated with poor overallsurvival in both the training and validation cohorts, independent
of TNM staging, and was associated with a poor therapeutic out-
come (adjuvant chemotherapy). But still little is known about
miR-21 function in CRC, the overexpression in CRC samples has
been conﬁrmed several times, we also know it is correlated with
advanced disease; the involvement of miR-21 in different types of
cancer suggests that it may have a general role in tumorigenesis,
but still concrete explanations of its role have not been proposed
[26].
Another actor, miR-29a, has been found to be up-regulated in
CRC versus normal tissue (tested in plasma, primary tumor tissue
and paired normal tissue) [27], and in 2012 it was proposed as a
potential serum marker for early detection of CRC [28].
In a recent publication, based on fresh frozen and FFPE surgi-
cally resected tissues (SRTs), only one miRNA, miR-150, was found
to be consistently and progressively deregulated in a collection of
adenomas and carcinomas, with lower expression compared to
normal tissue [29]. In two series of respectively 239 and 185 pa-
tients assessed by RT-PCR respectively by ISH, low expression of
miR-150 was associated with worse survival; curiously, a similar
result was previously reported in a study of sepsis [30].
In regard of the physiology of CRC, it can be divided broadly into
two groups: those exhibiting microsatellite instability and a high
frequency of point mutations (MSI) and those with stable micro-
satellites (MSS), which almost invariably show chromosomal insta-
bility (CIN) with higher frequency of diploids and focal copy
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cases represent about 10–15% of all CRC and are associated with
distinctive pathologic features, such as proximal location, poor dif-
ferentiation, frequent mucinous and medullary phenotype, and
marked peritumoral and intratumoral lymphocytic inﬁltration .
MSI carcinomas have a more favorable clinical outcome than
MSS (microsatellite stable) tumors and the survival advantage con-
ferred by the MSI phenotype is independent of tumor stage and
other clinical and pathological variables [31]. Members of the
oncogenic miR-17-92 family (miR-17-5p, miR-20, miR-25, miR-92-
1, miR-92-2, miR-93-1 and miR-106a) were found signiﬁcantly up-
regulated in MSS vs.MSI fresh frozen tumor samples [32]; but these
ﬁndings were only partially conﬁrmed by subsequent studies on
FFPE tissues [31].
Concerning the CIN pathway, in which the adenomatous polyp-
osis coli (APC) gene plays a dominant role, Nagel et al. showed that
miR-135a andmiR-135b directly target the 30 untranslated region of
APC, suppress its expression and induce higher activity in the Wnt
signaling pathway although without proof that this is relevant
in vivo or during CRC oncogenesis by analyzing colon cancer cell
lines (CCCLs), fresh frozen and FFPE CRC tissue and normal epithe-
lium [33]. Nevertheless, miR-135b was also found over-expressed
in inﬂammatory bowel disease, a condition that can lead to CRC.
In mouse models, treatment with anti-miR-135b resulted well dif-
ferentiated in tumors whereas those in the control groups showed
low differentiation.
Along with studies of single or few miRNAs, it has become clear
in the last years, that if we want to understand miRNAs biology and
functional role, they must be studied in combination among them
and with other omics data.
For example, the group of Volinia found networks of miRNAs in
normal tissues and in their pathologic counterparts (more than
3000 tumor tissue samples were studied) which deﬁned indepen-
dently regulated miRNAs, and target genes of uncoordinated
miRNAs involved in cancer-speciﬁc pathways [34]. Software
Applications that can help scientists to study the interactions
between genomics data and the pathways in which they are in-
volved include MetaCore (http://www.genego.com/metacore.php),
Ingenuity (http://www.ingenuity.com/), and Cytoscape (http://
www.cytoscape.org/).
For our understanding of the role of miRNAs in cancer, it is
essential to move on from reports of mere associations to knowl-
edge of how single miRNAs are functionally related to each other
and connected to the expression of proteins in the cell. For exam-
ple, several methods have become available for identifying miRNA
target sites (see Table 2), but the mere presence of a miRNA-bind-
ing site is insufﬁcient for predicting target regulation. Regulation of
targets by miRNAs is subject to various levels of control. The ﬁnd-
ing that any messenger RNA and RNA molecule can sequester miR-
NA molecules acting as ‘‘competing endogenous RNAs’’: ceRNAs
has shown that targets can reciprocally manage the function of
miRNAs. This interconnected regulation of miRNAs and target
genes needs to be further clariﬁed in order to understand to what
extent miRNAs regulate genes.
This represents a way forward in the myriad of data, the inte-
gration of miRNA and target genes to identify ‘‘network’’ deregula-
tion is still in its infancy, and there are few examples where we
begin to unravel the possible role that miRNAs in tumour cells in
tumorigenesis and tumour progression and metastasis.
Many are the open questions: it remains to be understood how
miRNAs differentiate low from high microsatellite instability, how
they are expressed in mutational subgroups like KRAS, BRAF and
BRAF-like mutated patients. Among these subgroups, are miRNAs
speciﬁc of a particular mutation? Each study should be ideally lead
by a consortium of partners allowing miRNAs to be studied to-
gether with mutational proﬁles, clinical-pathological variables,mRNAs expression, veriﬁcation of published subgroups and signa-
tures to avoid cases like those reported by Roepman et al., in NSCLC
where 8 previously published gene expression signatures were al-
most disjoint [35]. At least two large independent cohorts should
be always available for discovery and validation. For example, Chen
and colleagues [36] studied the role ofmiR-143 as target of KRAS in
CRC, the study provides the ﬁrst evidences that miR-143 is signiﬁ-
cant in suppressing CRC cell growth through inhibition of KRAS
translation, but how miR-143 able to distinguish between KRAS
mutated and WT patients is? Only 13 paired samples were ana-
lyzed, what happens if we analyze a larger cohort, are there other
sub-groups of patients? And if we have the opportunity to extract
normal tissue from different sites, what are we going to discover
[37]? Furthermore, if we consider that for FDA omic signatures
are medical devices [38], should not we, as research community,
have a register of negative results? In this framework, it is clear
how the importance of consortiums, large heterogeneous team
works, research networks like TCGA (http://cancergenome.nih.
gov/) along with projects like p-medicine (http://www.p-medi-
cine.eu) and VPH-NoE (http://www.vph-noe.eu/), that contribute
to the integrative omics study, data sharing, data mining, privacy,
access and ethical issues, toward research driven by interdisciplin-
ary discussions, are going to lead the research ﬁeld, not only in
terms of transparency and scientiﬁc results but also in term of
better prospective treatment, health and well-being for patients
as well as decision support for clinicians.3. miRNAs as candidate biomarkers for targeted therapies?
The ability to detect miRNAs in body ﬂuids, such as serum and
plasma, along with their role in cancer progression raised the ques-
tion if they could be used as convenient diagnostic biomarkers and
for monitoring therapy response. Wu and colleagues found that a
mutation downstream of let-7e resulted in a signiﬁcant reduction
of its expression in vivo, suggesting that screening for genetic vari-
ations in miRNA genes in human cancers has potential for identiﬁ-
cation of molecular diagnostic and therapeutic targets [39]. They
screened sequence variations in 300 miRNAs from 150 patients
(mainly from human colon and prostate cancer patients) and in 20
human tumor cell lines. Interestingly, they found that a germ line
mutation located downstream of the pre-let-7emiRNA led to a sig-
niﬁcant reduction of its expression. This underpins the potential
use of circulating miRNAs as a biomarker for cancer detection
although we would think that somatic mutations detected in blood
might be indicating presence of a cancer, but population polymor-
phisms (germ line mutations) maybe indicate a heritable risk but
not yet presence of cancer. Along these lines, miR-144⁄ has been
found as a potential diagnostic biomarker for CRC in the feces [40].
There are cases in which the analysis’s focus is on only one
miRNA, especially when it is observed as a speciﬁc candidate that
characterizes a sub-group of CRC patients, examples are the roles
of let-7a andmiR-143 that were found to depend on KRAS mutation
[41–43].
Anti-EGFR target therapy has been extensively used in all mCRC
patients until unresponsiveness of KRAS mutated patients to this
therapy was discovered [44].
Since then, retrospective studies on patients KRAS-mutated
treated with anti-EGFR have been very useful in understanding po-
tential mechanisms that allow identifying KRAS-mutated patients
that can still beneﬁt from the anti-EGFR therapy. There is a ﬁrst
indication that among patients with mCRC (refractory to irinotec-
an) those with tumors KRAS mutated with a T > G base change in
the let-7a KRAS mRNA binding site (rs61764370) might have high-
er chances of survival (overall and progression free) when let-7a is
highly expressed [42].
Table 2
Commonly used miRNA target prediction software (in chronological order per category).
Category Program Main feature(s) Website
Seed-based miRanda Identiﬁes maximum local complementarity between the 30 untranslated region and the miRNA,
which is further ﬁltered using the binding energy of the duplex and evolutionary conservation in
multiple genomes
http://www.microrna.org/
microrna/home.do
PicTar Identiﬁes targets on the basis of sequence complementarity between single or multiple miRNAs
and the 30 untranslated region
http://pictar.mdc-berlin.de/
TargetScan Incorporates the ‘‘offset 6mer’’ miRNA binding site, probability of conserved targeting, and
multiple miRNA ‘‘context scores’’ reﬂecting various features of miRNA–mRNA binding
http://www.targetscan.org/
DIANA-
microT 3.0
Identiﬁes conserved and non-conserved miRNA recognition elements, providing conﬁdence
scores for each prediction that correlate with protein expression levels
http://diana.cslab.ece.ntua.gr/
microT/
Pattern-based Rna22 Identiﬁes putative target islands on the basis of patterns that are conserved within the miRNA
sequences of the same or different organisms, then examines whether the miRNA query sequence
can form heteroduplexes with the identiﬁed target island that satisfy the user’s parameter
settings
http://cbcsrv.watson.ibm.com/
rna22.html
http://cm.jefferson.edu/
rna22v1.0/
Machine
learning
miTarget2 Support vector machine classiﬁer, trained on multiple microarray datasets, that can identify
miRNA–mRNA-degraded targets
http://mirdb.org
NBmiRTar Uses both ‘‘seed’’ and ‘‘out-seed’’ segments of the miRNA–mRNA duplex and can be used to
further ﬁlter output ﬁles from miRanda
http://wotan.wistar.upenn.edu/
NBmiRTar/login.php
TargetMiner Uses an experimentally validated (by protein and mRNA levels) negative training dataset to train
the support vector machine classiﬁer and identify unique miRNA–mRNA duplex features to use
for target prediction
http://www.isical.ac.in/
bioinfo_miu/
targetminer20.htm
Targets
secondary
structures
PITA Focuses on target-site accessibility by calculating the difference between energy gained from the
formation of the miRNA–mRNA duplex and energy required to unfold the miRNA binding site on
the mRNA target
http://genie.weizmann.ac.il/
pubs/mir07/
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unresponsive patients to EGFR-targeted therapy (approximately
35–45%), and miRNAs became good candidates in the character-
ization of other patients that are KRAS wild type but still unrespon-
sive to the anti-EGFR therapy [45].
miR-143 low expression has been shown to be predictive of
poor prognosis (using cancer-speciﬁc survival as end-point) among
patients that are KRAS wild type but unresponsive to EGFR tar-
geted therapy, suggesting that miR-143 might be a prognostic bio-
marker in this subgroup [43].
In other cases, patterns (modules) of miRNAs distinguish among
classes of samples, like in a recent paper, where samples of non-
neoplastic mucosa, low- and high-grade dysplasia in adenoma
and invasive adenocarcinoma of the colon (FFPE) have been
hybridized in microarrays to highlight modules of miRNAs that
systematically change their regulation during tumor development
and progression [46].
When studying the miRNAs functional involvement in cancer is
also important to distinguish between mature sequences of the
same step loop miRNA. For example, a study of the regulation of
the expression of the miRNAsmiR-28-3p andmiR-28-5p has shown
that they are diverse not only in the mRNAs they target but also in
the regulation of their expression. miR-28-5p and miR-28-3p are
down regulated in CRC whereas miR-28-5p altered the expression
of CCND1 and HOXB3 and miR-28-3p bound NM23-H1. Overex-
pression of miR-28-5p reduced CRC cell proliferation, migration
and invasion in vitro, whereasmiR-28-3p increased CRC cell migra-
tion and invasion in vitro [47].
In unraveling these complex functional relations, robust meth-
odology for measuring miRNAs and normalization of qRT-PCR data
are essential [48].
3.1. Pros and cons
3.1.1. Diagnostic, prognostic and predictive applications
miRNAs potentially constitute effective diagnostic markers for
cancer. Individual expression levels of particular miRNAs might
be associated with risk of cancer relapse. In this regard, the stabil-
ity of particular miRNAs in FFPE tissues, the need of little tissue
(allowing assessment in small biopsies) and their presence in bodyﬂuids is a potential advantage [15]. However, standardized meth-
ods for predicting and sequencing miRNAs and miRNA targets re-
main to be developed. The biomedical and bioinformatics
research community is working to ﬁll in these gaps in miRNA re-
search that remain so that the ﬁndings can be translated into clin-
ical practice.
If miRNAs are intended to be used as biomarkers, therapeutic
targets or therapeutic agents, consistency of results and methodo-
logical considerations will become increasingly important. The sig-
niﬁcance of these ﬁndings and potential roles as molecular
classiﬁers or clinical biomarkers will require very well-supported
validation in larger cohort studies.
3.1.2. Therapeutic applications
Given the role that certain miRNAs might have in driving dis-
ease, intervention on their expression may represent a rationale
for new treatment modalities. Proof of principle has been provided
in vitro for miR-30bnc, miR-221 and miR-222 which are involved in
the modulation of geﬁtinib-induced apoptosis in Non-Small Cell
Lung Cancer [49].
miRNAs need only partial sequence match to a target mRNA to
repress gene expression. However, they do share the same gene-
silencing machinery to silence target gene expression. Therapeutic
approaches based on miRNA and siRNA have intrinsic similarities
and differences. Therefore, the potential clinical beneﬁts of modu-
lating miRNAs can be explored from parallel studies of siRNA in
cancer therapies, but with caution due to the intrinsic differences
[50]. While the risk of toxicity might be reduced when we will have
a better understanding the feedback mechanisms in the miRNA
cellular processing, potential toxicity from off-target effects and
immune activation during treatment (with miRNAs) appear to be
relevant.
Therefore, when designing miRNA approaches, we need to use
the most potent miRNA candidate at lowest concentration possible
to interfere with tumor growth.
The fact that one miRNA usually regulates multiple genes adds a
unique layer of complexity to miRNA therapy, which might render
it difﬁcult to control in practive. The use of tumor-speciﬁc delivery
agents, such as tumor-speciﬁc nanoparticles or viral vectors, as has
been demonstrated to work for siRNA in humans, may obviate at
S. Rossi et al. / FEBS Letters 586 (2012) 3000–3007 3005least concerns regarding speciﬁc delivery. In patients with solid
cancers, siRNA has been intravenously administered using targeted
nanoparticles. Post treatment analysis showed that siRNA treat-
ment remains effective after several cycles of administration which
provides the ﬁrst example of dose-dependent accumulation of tar-
geted nanoparticle in human tumors. These data demonstrate that
RNAi treatment is in principle feasible in patients using systemi-
cally delivered siRNA, and that siRNA can be used as a gene-speciﬁc
therapeutic approach. With a better understanding of the role of
miRNAs in tumor progression and a more sophisticated design of
miRNA-modulating molecules, miRNA-mediated therapy will
likely start providing new therapeutic options to be tested in clin-
ical trials. It seems reasonable to postulate for the not so distant fu-
ture that the analysis of cancer genome sequences and the use of
omics based biomarkers will become important tools in the con-
duct of clinical trials and ultimately ﬁnd their ways into daily clin-
ical practice.4. Conclusions
miRNAs have several properties that could make them effective
diagnostic markers for cancer, for example, measuring a patient’s
expression levels of speciﬁc miRNAs could help a clinician decide
whether the patient is at risk for developing cancer or whether the
patient’s tumor has metastasized. The stability of miRNAs in FFPE
tissues and body ﬂuids is advantageous for biomarker discovery
and validation; furthermore miRNAs can be extracted from small
biopsy specimens. In addition, miRNAs are potential therapeutic
agents for personalized cancer management. The research commu-
nity is working toward switching from potentiality to reality.
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